CTRI Number |
CTRI/2020/05/025214 [Registered on: 15/05/2020] Trial Registered Prospectively |
Last Modified On: |
13/04/2021 |
Post Graduate Thesis |
No |
Type of Trial |
Interventional |
Type of Study
|
Drug Ayurveda |
Study Design |
Randomized, Parallel Group, Active Controlled Trial |
Public Title of Study
|
To observe the effect of Ayurvedic medicine for the treatment of COVID-19 |
Scientific Title of Study
|
A Randomized, Open Label, Parallel Efficacy, Active Control, Exploratory Clinical Trial to Evaluate Efficacy and Safety of an Ayurvedic Formulation (AYUSH 64) as Adjunct Treatment to Standard of Care for the management of Mild to Moderate COVID-19 Patients |
Secondary IDs if Any
|
Secondary ID |
Registry |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
Modification(s)
|
Name |
Dr Sumit Shrivastva |
Address |
77, Chandi Path, Sector 46B, Sector 46
Ward No. 1 to 5 (General ward Male and Female) Chandigarh CHANDIGARH 160047 India |
Phone |
9781110780 |
Fax |
|
Email |
sumitpankaj@gmail.com |
|
Details Contact Person Scientific Query
Modification(s)
|
Name |
Dr Sumit Shrivastva |
Address |
77, Chandi Path, Sector 46B, Sector 46
Room No. 116, Ground floor,
Shri Dhanwantry Ayurvedic Hospital Chandigarh CHANDIGARH 160047 India |
Phone |
9781110780 |
Fax |
|
Email |
sumitpankaj@gmail.com |
|
Details Contact Person Public Query
Modification(s)
|
Name |
Dr Sumit Shrivastva |
Address |
77, Chandi Path, Sector 46B, Sector 46
Room No. 116, Ground floor,
Shri Dhanwantry Ayurvedic Hospital Chandigarh CHANDIGARH 160047 India |
Phone |
9781110780 |
Fax |
|
Email |
sumitpankaj@gmail.com |
|
Source of Monetary or Material Support
|
Central Council for Research in Ayurvedic Sciences, New Delhi |
|
Primary Sponsor
|
Name |
Central Council for Research in Ayurvedic Sciences |
Address |
Jawahar Lal Nehru Bhartiya Chikitsa Evam Homoeopathy Anusandhan Bhawan 61-65, Institutional Area, Opposite D-Block, Janakpuri, New Delhi-110058
|
Type of Sponsor |
Government funding agency |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
Modification(s)
|
No of Sites = 1 |
Contact Person |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Sumit Shrivastva |
Shri Dhanwantry Ayurvedic College and Hospital |
Room No. 116, Ground floor,
Shri Dhanwantry Ayurvedic Hospital
77, Chandi Path, Sector 46 B, Sector 46 Chandigarh |
9781110780
sumitpankaj@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Institute Ethics Committee Central Ayurveda Research Institute for Respiratory Disorders Moti Bagh Road Patiala Punjab 147001 |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
Modification(s)
|
Health Type |
Condition |
Patients |
Coronavirus as the cause of diseases classified elsewhere |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Intervention |
AYUSH 64 |
Dose:2 capsules (500 mg each) thrice daily
Dosage form:Capsules/Tablets
Route of Administration: Oral
Time of Administration: Thrice a day after food
Anupana: Water
Duration of therapy: 30 days
|
Comparator Agent |
Conventional standard therapy for COVID-19 positive patients |
Conventional standard therapy as per ICMR/WHO parameters |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
75.00 Year(s) |
Gender |
Both |
Details |
1.Typical clinical presentation of acute onset febrile illness with cough and a RT_PCR based laboratory confirmation test for COVID-19
2.Typical clinical presentation of acute onset febrile illness with sore throat and dry cough with or without shortness of breath in a patient from a known ‘hot spot’ area or in close contact with a confirmed COVID-19 case with a negative laboratory test for COVID 19 and H1N1 influenza
3.Patients with either sex, 18 to 75 years age
4.Patients with mild-moderately severe disease
5.All patients must agree not to share medication
6.Patients willing to participate and sign an informed consent Understands and agrees to comply with planned study procedures.
7.Agrees to the give OP swabs and venous blood for testing as per protocol.
|
|
ExclusionCriteria |
Details |
1. Patients suffering from severe COVID-19 Disease as judged by a physician and fulfilling at least two of the following three criteria (i) Respiratory distress at room ambience (equal or more than 30 breaths per min) (ii) Oxygen saturation at rest equal or less than 93% (peripheral digital arterial oxymetry) and requiring oxygen support for over one hour to normalize (iii) Any of the known COVID-19 complications and emergency procedures which may require shift/admission in intensive care unit such as respiratory failure, adult respiratory distress syndrome, requirement of oxygen support for over 1 hour, requirement of mechanical ventilation, septic shock, or severe non-respiratory organ dysfunction or failure.
2.Chronic, Severe, Unstable, Uncontrolled co-existent medical illness such as Diabetes, Hypertension, Cardiac disorders, liver, kidney disorders and lung disorders or other disease of concern which may put the patient at increased risk during the study
3. History of immunosuppression: solid organ or bone marrow transplant, use of immunosuppressive antimetabolic and biologic agents, intrinsic immunodeficiencies, HIV infection.
4. Active cancer diagnosis, on palliative treatment or requiring current therapy with antimetabolic agents, immunotherapy or radiotherapy.
5. Patients on parenteral nutrition
6. Patients with known sensitivity or contraindication to any of the ingredients of study medication
7. History of bleeding haemorrhoids, haemoptysis, acid peptic diseases, ulcers and pulmonary diseases (tuberculosis, asthma, etc.)
8. Patients who are likely to worsen or planed ICU admission or ventilator support due to any reason
9. Pregnancy and lactation
10. Participation in a drug interventional clinical drug trial of any nature in the three month period preceding onset of COVID-19
11. Participation in any other clinical trial of an experimental agent treatment for COVID-19
12. Patients on any kind of Ayurveda treatment or any other alternative and complementary medicinal systems such as Homeopathy, Unani, Siddha and in particular requiring oral therapy of any kind.
13. Physician decision that involvement in the study is not in the patient´s best interest
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
Method of Concealment
|
An Open list of random numbers |
Blinding/Masking
|
Open Label |
Primary Outcome
|
Outcome |
TimePoints |
a) Mean time (days) for clinical recovery [Day of randomization to the day of clinical recovery
b) Proportion of patients showing ‘clinical recovery’.
|
On 7th day, 15th day, 23rd day and 30th day |
|
Secondary Outcome
|
Outcome |
TimePoints |
Improvement in the symptoms,supported by in lab investigations and other radiological examination |
On baseline and 30th day |
|
Target Sample Size
|
Total Sample Size="80" Sample Size from India="80" |
Phase of Trial
|
Phase 2/ Phase 3 |
Date of First Enrollment (India)
|
24/05/2020 |
Date of First Enrollment (Global) |
No Date Specified |
Estimated Duration of Trial
|
Years="0" Months="6" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Applicable |
Recruitment Status of Trial (India) |
Completed |
Publication Details
Modification(s)
|
under publication |
Brief Summary
|
COVID-19 has emerged as the latest pandemic, that erupted in the
Wuhan City of People’s Republic of China in December 2019, which is affecting
human health and economy across the world. 1133758 cases have been reported
globally as on April 5, according to the WHO Coronavirus disease 2019
(COVID-19) Situation Report – 76. The occurrence of the ongoing COVID-19 in
developed countries also highlights the fact that developed countries and rich
populations are not immune to the outbreaks of infectious diseases.
Coronaviruses (CoVs) belong
to the family Coronaviridae and are enveloped, single-stranded, positive-sense
RNA viruses. The SARS-CoV-2 belongs to the beta CoV genus which also includes
the SARS-CoV-1 and the MERS-CoV. The lack of approved effective drug
therapeutic protocols for CoVs would be a challenge for the treatment of the
newly emerged COVID-19 infections worldwide.
Drug repurposing, which is
defined as identifying alternative uses for approved or investigational drugs
outside their defined indication, could be a possible way to overcome the time
limitation of research and development needed to design a therapeutic drug to
combat the pathogen. The drug repurposing or repositioning approach thus can
facilitate prompt clinical decisions at lower costs than de novo drug
development.
Though drug repurposing is sometimes based on chance observations, target-based
repurposing of drugs depends on prior understanding of the precise molecular or
cellular element that is recognized by the proposed drug.
Ayurveda and traditional systems of Medicine in India have been
treating diseases of infectious and non-infectious origin equally with expansive
success rates, treating the patients through an individualized person to person
approach depending upon the presentation of clinical symptoms in each. Central Council for Research in
Ayurvedic Sciences, apex body for research and development in Ayurveda in India
under Ministry of AYUSH has developed a poly-herbal drug ‘AYUSH 64’ through
extensive pharmacological, toxicological and clinical studies. The
experimental studies of AYUSH 64 has shown that it was safe and non-toxic in the
dose of 500 mg/kg of body weight for 12 weeks. It is found to be effective in fevers of unknown
etiology, filarial lymphangitis and derangement of liver function besides its
anti-malarial activity.
Taking leads from the clinical experiences of
physicians who had successfully used AYUSH-64, for management of Influenza like
Illness (ILI), a pilot study was conducted by this Council, which was concluded
recently and is under the process of publication. This study was done in 30
cases of flu like illness, among whom, 28 participants recovered without any
further medication. This lead to the idea of repurposing AYUSH 64 for use in
the management of Covid-19 positive cases which also present with Influenza
like symptoms owing to affliction of respiratory tract. The composition of
AYUSH 64 includes, Saptaparna (Alstonia scholaris R. Br.) Katuki
(Picrorhiza kurroa Royle ex. Benth), Kiratatikta (Swertia
Chirata Pexbex. Karst) and Kuberaksha (Caesalpinia crista
Linn.). Studies on the ingredients of AYUSH-64 has shown
anti-inflammatory and immunomodulatory activities. Animal study has
demonstrated that total alkaloids from Saptaparna inhibited the
production of inflammatory cytokines TNF-α and IL-8 in the BALF and lung. Swertia chirata showed antiviral properties against Herpes simplex virus
type-1 and crude extract of the whole Swertia chirata plant inhibited the
expression of Vpr in Hela cells harboring the TREx plasmid encoding full-length
Vpr (TREx-HeLa-Vpr cells). |